Literature DB >> 26773823

Cancer care cost trends in the United States: 1998 to 2012.

James A Lee1, Charles S Roehrig1, Erin Duggan Butto1.   

Abstract

BACKGROUND: The authors examine trends in spending on cancer from 1998 through 2012, including cancer care costs, prevalence, and cases by payer, and discuss the results within the context of a prior analysis and recent health policy and programmatic changes.
METHODS: Condition-specific distribution of expenditures from the Medical Expenditure Panel Survey, supplemented with results from the National Nursing Home Survey and other data sources, was used as the basis for allocating the Personal Health Care components of the National Health Expenditure Accounts among conditions.
RESULTS: Cancer care expenditures grew at an annualized rate of 2.9% from 1998 to 2012. The share of expenditures for hospital-based care declined to a low of 48% during 2007 through 2009. Professional and clinical services' shares declined substantially between 2007 to 2009 and 2010 to 2012 when the hospital share increased. Treated prevalence decreased for all payers between the first and last study periods with the exception of private payers (11.2% increase). Out-of-pocket expenditures declined to 4.7%, whereas Medicare's share increased slightly. Medication expenditures increased, notably within retail and mail order settings.
CONCLUSIONS: The previous rapid growth of cancer prevalence and expenditures has now slowed, most remarkably since the 2007 recession. Out-of-pocket expenses for cancer treatment continue to decline, most recently reaching the lowest point in 25 years. In addition, the early effects of Affordable Care Act expansion can be observed in the decline of treated prevalence in the Medicaid population as the demographics of Medicaid enrollees change.
© 2016 American Cancer Society.

Entities:  

Keywords:  Healthcare Cost and Utilization Project; Medicaid; Medical Expenditure Panel Survey; Medicare; cancer; cost of illness; health insurance; medical expenditures; out-of-pocket costs

Mesh:

Year:  2016        PMID: 26773823     DOI: 10.1002/cncr.29883

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation.

Authors:  K Robin Yabroff; Cathy Bradley; Ya-Chen Tina Shih
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

2.  Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.

Authors:  Ashley M Perry; Andrew M Brunner; Tao Zou; Kristin L McGregor; Philip C Amrein; Gabriela S Hobbs; Karen K Ballen; Donna S Neuberg; Amir T Fathi
Journal:  Cancer       Date:  2017-05-02       Impact factor: 6.860

3.  Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Authors:  Scott K Sherman; Joel J Lange; Fadi S Dahdaleh; Rahul Rajeev; T Clark Gamblin; Blase N Polite; Kiran K Turaga
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

Review 4.  Financial Hardships Experienced by Cancer Survivors: A Systematic Review.

Authors:  Cheryl K Altice; Matthew P Banegas; Reginald D Tucker-Seeley; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

5.  Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers.

Authors:  John M Salsman; Suzanne C Danhauer; Justin B Moore; Edward H Ip; Laurie E McLouth; Chandylen L Nightingale; Christabel K Cheung; Kristin M Bingen; Reginald D Tucker-Seeley; Denisha Little-Greene; Dianna S Howard; Bryce B Reeve
Journal:  Cancer       Date:  2021-04-13       Impact factor: 6.921

Review 6.  Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews.

Authors:  Hossein Mashhadi Abdolahi; Ali Sarabi Asiabar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Aziz Rezapour
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.